Evidence map›Paper›PMID 26108222›Full record

Trial reportThe international journal of neuropsychopharmacology2015

Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.

Patrick C Dolder, Yasmin Schmid, Manuel Haschke, Katharina M Rentsch, Matthias E Liechti

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  18. Review
  19. Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Patrick C DolderDivision of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research (Mr Dolder, and Drs Schmid, Haschke, and Liechti), and Laboratory Medicine (Mr Dolder and Dr Rentsch), University Hospital and University of Basel, Basel, Switzerland.
Yasmin SchmidDivision of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research (Mr Dolder, and Drs Schmid, Haschke, and Liechti), and Laboratory Medicine (Mr Dolder and Dr Rentsch), University Hospital and University of Basel, Basel, Switzerland.
Manuel HaschkeDivision of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research (Mr Dolder, and Drs Schmid, Haschke, and Liechti), and Laboratory Medicine (Mr Dolder and Dr Rentsch), University Hospital and University of Basel, Basel, Switzerland.
Katharina M RentschDivision of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research (Mr Dolder, and Drs Schmid, Haschke, and Liechti), and Laboratory Medicine (Mr Dolder and Dr Rentsch), University Hospital and University of Basel, Basel, Switzerland.
Matthias E LiechtiDivision of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research (Mr Dolder, and Drs Schmid, Haschke, and Liechti), and Laboratory Medicine (Mr Dolder and Dr Rentsch), University Hospital and University of Basel, Basel, Switzerland. matthias.liechti@usb.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pharmacokinetics of oral lysergic acid diethylamide are unknown despite its common recreational use and renewed interest in its use in psychiatric research and practice.

methodsWe characterized the pharmacokinetic profile, pharmacokinetic-pharmacodynamic relationship, and urine recovery of lysergic acid diethylamide and its main metabolite after administration of a single oral dose of lysergic acid diethylamide (200 μg) in 8 male and 8 female healthy subjects.

resultsPlasma lysergic acid diethylamide concentrations were quantifiable (>0.1 ng/mL) in all the subjects up to 12 hours after administration. Maximal concentrations of lysergic acid diethylamide (mean±SD: 4.5±1.4 ng/mL) were reached (median, range) 1.5 (0.5-4) hours after administration. Concentrations then decreased following first-order kinetics with a half-life of 3.6±0.9 hours up to 12 hours and slower elimination thereafter with a terminal half-life of 8.9±5.9 hours. One percent of the orally administered lysergic acid diethylamide was eliminated in urine as lysergic acid diethylamide, and 13% was eliminated as 2-oxo-3-hydroxy-lysergic acid diethylamide within 24 hours. No sex differences were observed in the pharmacokinetic profiles of lysergic acid diethylamide. The acute subjective and sympathomimetic responses to lysergic acid diethylamide lasted up to 12 hours and were closely associated with the concentrations in plasma over time and exhibited no acute tolerance.

conclusionsThese first data on the pharmacokinetics and concentration-effect relationship of oral lysergic acid diethylamide are relevant for further clinical studies and serve as a reference for the assessment of intoxication with lysergic acid diethylamide.

Indexed as

Administration, OralAdultChromatography, LiquidCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHalf-LifeHallucinogensHealthy VolunteersHumansLinear ModelsLysergic Acid DiethylamideMaleMiddle AgedOrganometallic Compounds2-oxo-3-hydroxylysergic acid diethylamideHallucinogensJM 2469Lysergic Acid DiethylamideOrganometallic CompoundsLSDO-H-LSDpharmacodynamicspharmacokineticsplasmaurine

Identifiers

PMID26108222
PMCPMC4772267

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.